Terence Friedlander, MD

Genitourinary oncologist

Dr. Terence Friedlander specializes in genitourinary cancer, in particular cancer of the bladder and prostate. His research interests focus on understanding the basic biology of these diseases and in developing new ways to overcome treatment resistance.

Friedlander earned a medical degree at New York University Medical School and completed a residency in internal medicine at UCSF. He received a Fulbright Scholarship in 2006 to study medical ethics and completed a fellowship in hematology and oncology at UCSF, when he served as chief fellow. He received an American Society of Clinical Oncology (ASCO) Young Investigator Award and is a member of the American Society of Clinical Oncology and American Association of Cancer Researchers. He is a clinical instructor in hematology and oncology at UCSF.


Cancer Immunotherapy Clinic
400 Parnassus Ave., 4th Floor
San Francisco, CA 94143
Phone for Existing Patients: (415) 353-2421
Phone for New Patients: (415) 353-2051

Hours: Monday to Friday, 8 a.m. – 5 p.m.

Genitourinary Medical Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 476-4616
Fax: (415) 353-7107

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Medical Oncology Phone: (415) 476-4616
Surgical Oncology Phone: (415) 353-7171
Medical Oncology Fax: (415) 353-7107
Surgical Oncology Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Medical Oncology, American Board of Internal Medicine

Academic Title

Associate Professor

More about Terence Friedlander

Additional Languages



New York University School of Medicine 2003


UCSF Medical Center, Internal Medicine 2006


UCSF Medical Center, Hematology-Oncology 2010

Selected Research and Publications

  1. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 Feb 27.
  2. Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018 Jan 25; 6(1):4.
  3. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.